AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
As of today, AbbVie(ABBV) shares are valued at $265.00. The company's market cap stands at 467.01B, with a P/E ratio of 74.96 and a dividend yield of 2.58%.
During the trading session on 2026-09-26, AbbVie(ABBV) shares reached a daily high of $266.00 and a low of $262.59. At a current price of $265.00, the stock is +0.9% higher than the low and still -0.4% under the high.
Trading activity shows a volume of 2.54M, compared to an average daily volume of 4.01M.
The stock's 52-week range extends from a low of $190.75 to a high of $269.39.
The stock's 52-week range extends from a low of $190.75 to a high of $269.39.
ABBV News
Key Points AbbVie continues to diversify its portfolio into neuroscience and aesthetics to offset the loss of patent exclusivity for older drugs. Johnson & Jo...
AbbVie (ABBV) just picked up a fresh regulatory win in oncology, with Health Canada granting a new follicular lymphoma indication for EPKINLY in combination the...
Choosing between AbbVie (ABBV +0.01%) and Eli Lilly and Co (LLY +2.69%) requires weighing established income against explosive growth. Both companies lead the p...
Analyst ratings
75%
of 32 ratingsMore ABBV News
AbbVie (NYSE:ABBV) has entered a multi year collaboration with Iambic to apply AI tools to small molecule discovery in immunology, neuroscience, and oncology....
Key Points Dividend payments offer you security in difficult markets -- and extra growth in better times. These pharma companies offer dividend yields that be...
AbbVie (ABBV) announced that the European Commission has approved Rinvoq for the treatment of active polyarticular juvenile idiopathic arthritis in patients two...
(RTTNews) - Monday, AbbVie Inc. (ABBV) announced a multi-year collaboration with Iambic, a clinical-stage life sciences and technology company, to accelerate th...
Key Points AbbVie's Qulipta could be racing toward another label expansion, given a recent clinical trial win. This new indication could make a meaningful imp...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.